SeqLL Announces CRADA with the FBI
February 07 2023 - 07:30AM
GlobeNewswire Inc.
SeqLL Inc. (“SeqLL”, NASDAQ: SQL), a technology company providing
life sciences instrumentation and research services, today
announced the establishment of a two-year Cooperative Research and
Development Agreement (CRADA) with the U.S. Department of Justice’s
Federal Bureau of Investigation (FBI). Under this CRADA, SeqLL and
the FBI Laboratory Division (FBI LD) will seek to evaluate and
determine the forensic capabilities of direct RNA sequencing using
SeqLL’s True Single Molecule Sequencing (tSMS®) platform.
The FBI LD and SeqLL will collaborate with a goal of producing
an assay for forensic body fluid identification, without
compromising traditional STR or DNA sequence analysis. This
agreement is among the first times the FBI is utilizing the CRADA
mechanism to further develop laboratory capabilities.
CRADAs enable the sharing of resources and expertise for
collaborative research that advances the FBI mission. “Body fluid
identification can provide investigative context and have probative
value. We are excited to collaborate with SeqLL to evaluate the
potential of this capability in forensic casework,” said Eric
Pokorak, Assistant Director, FBI Laboratory Division.
“We are delighted to be working with a motivated and
knowledgeable partner, such as the FBI LD. We appreciate the
opportunity this CRADA provides, to methodically develop forensic
applications utilizing SeqLL’s technology,” said Daniel Jones,
SeqLL CEO and Founder. “We look forward to demonstrating how
single-molecule, PCR-free approaches are ideally suited for this
space.”
About the FBI’s Laboratory DivisionThe FBI
conducts research and development activities as a recognized
federal laboratory. This CRADA will support the FBI LD, a division
within the Scientific and Technology Branch, whose mission is to
collect, analyze and share timely scientific and technical
information. The FBI LD’s primary locations are the FBI Academy in
Quantico, VA and FBI Redstone in Huntsville, AL.
About SeqLL Inc.SeqLL Inc. (“SeqLL”) is a
technology company providing life sciences instrumentation and
research services in collaborative partnerships aimed at the
development of novel scientific assets and intellectual property
across multiple “omics” fields. The Company leverages its expertise
with the True Single Molecule Sequencing (“tSMS®”) platform to
empower scientists and researchers with improved genetic tools to
better understand the molecular mechanisms of disease that is
essential to the continued development of new breakthroughs in
genomic medicine, and that hopefully address the critical concerns
involved with today’s precision medicine.
Forward Looking StatementsThis press release
contains certain forward-looking statements, including those
related to the applicability and viability of the
Company’s technology to quantifying RNA molecules from
blood and other statements that are predictive in nature.
Forward-looking statements are based on the Company's current
expectations and assumptions. The Private Securities Litigation
Reform Act of 1995 provides a safe-harbor for forward-looking
statements. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. Prospective investors
are cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this presentation.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements are set forth in the Company's filings
with the Securities and Exchange Commission, including its
registration statement on Form S-1, as amended, under the caption
“Risk Factors.”
Contacts:
Brian ParasChief Business OfficerTel: +1 (508)
847-7711Email: bparas@seqll.com
SeqLL (NASDAQ:SQL)
Historical Stock Chart
From Apr 2023 to May 2023
SeqLL (NASDAQ:SQL)
Historical Stock Chart
From May 2022 to May 2023